- Home
- DBI vs SGMO Comparison
DBI vs SGMO Comparison
Compare DBI & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBI
- SGMO
- Stock Information
- Founded
- DBI 1991
- SGMO 1995
- Country
- DBI United States
- SGMO United States
- Employees
- DBI N/A
- SGMO N/A
- Industry
- DBI Clothing/Shoe/Accessory Stores
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DBI Consumer Discretionary
- SGMO Health Care
- Exchange
- DBI Nasdaq
- SGMO Nasdaq
- Market Cap
- DBI 138.7M
- SGMO 122.8M
- IPO Year
- DBI 1991
- SGMO 2000
- Fundamental
- Price
- DBI $4.26
- SGMO $0.54
- Analyst Decision
- DBI Hold
- SGMO Strong Buy
- Analyst Count
- DBI 2
- SGMO 7
- Target Price
- DBI $4.00
- SGMO $5.29
- AVG Volume (30 Days)
- DBI 999.4K
- SGMO 5.5M
- Earning Date
- DBI 09-09-2025
- SGMO 08-07-2025
- Dividend Yield
- DBI 4.23%
- SGMO N/A
- EPS Growth
- DBI N/A
- SGMO N/A
- EPS
- DBI N/A
- SGMO N/A
- Revenue
- DBI $2,949,575,000.00
- SGMO $81,706,000.00
- Revenue This Year
- DBI N/A
- SGMO $21.24
- Revenue Next Year
- DBI $2.45
- SGMO N/A
- P/E Ratio
- DBI N/A
- SGMO N/A
- Revenue Growth
- DBI N/A
- SGMO 565.52
- 52 Week Low
- DBI $2.18
- SGMO $0.41
- 52 Week High
- DBI $7.46
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- DBI 65.96
- SGMO 50.65
- Support Level
- DBI $3.65
- SGMO $0.47
- Resistance Level
- DBI $4.80
- SGMO $0.56
- Average True Range (ATR)
- DBI 0.27
- SGMO 0.03
- MACD
- DBI 0.10
- SGMO -0.00
- Stochastic Oscillator
- DBI 71.83
- SGMO 55.38
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.